Skip to main content
. Author manuscript; available in PMC: 2013 Feb 8.
Published in final edited form as: J Hypertens. 2012 Sep;30(9):1766–1774. doi: 10.1097/HJH.0b013e328356766f

TABLE 1.

Body weight, arterial pressure, heart rate, isoprostane, PRC, cardiac NOx and fibrosis in nebivolol-treated SHRs fed HSD

Control High salt High salt and nebivolol
Body weight (g) 304 ± 4 233 ± 9* 264 ± 4*,#
SAP (mmHg) 194 ± 6 234 ± 9* 235 ± 8*
DAP (mmHg) 145 ± 6 175 ± 5* 170 ± 5*
MAP (mmHg) 168 ± 6 201 ± 6* 197 ± 6*
HR (beats/min) 433 ± 11 391± 11* 358 ± 9*,#
Plasma 8-isoprostane (pg/ml) 133 ± 20 538±116* 133±13*
PRC (ng/ml per h) 2.08 ± 0.59 12.23 ± 3.24* 1.21 ± 0.58*
Cardiac NOx (μg/mg protein) 0.11 ± 0.01 0.14 ± 1.01 0.12 ± 0.01
Fibrosis (% of total area) 3.41 ± 0.48 13.05 ± 2.38* 6.26 ± 0.97*

Results are mean ± SEM. DAP, diastolic arterial pressure; HR, heart rate; MAP, mean arterial pressure; NOx, nitric oxide metabolites (nitrite and nitrate); PRC, plasma renin concentration; SAP, systolic arterial pressure.

*

P<0.05 vs. control.

#

P< 0.05 vs. untreated salt-loaded group.